BSE Live
Oct 03, 16:01Prev. Close
9221.25
Open Price
9259.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 03, 15:59Prev. Close
9222.00
Open Price
9248.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
9331.00 (40)
Key Financial Ratios of AstraZeneca Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
Per Share Ratios | ||||||
Basic EPS (Rs.) | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 | |
Diluted EPS (Rs.) | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 | |
Cash EPS (Rs.) | 62.29 | 70.58 | 46.22 | 31.42 | 45.37 | |
Book Value [ExclRevalReserve]/Share (Rs.) | 308.14 | 284.77 | 235.48 | 204.56 | 182.47 | |
Book Value [InclRevalReserve]/Share (Rs.) | 308.14 | 284.77 | 235.48 | 204.56 | 182.47 | |
Dividend / Share(Rs.) | 32.00 | 24.00 | 16.00 | 10.00 | 2.00 | |
Revenue from Operations/Share (Rs.) | 686.52 | 518.21 | 401.19 | 322.24 | 325.42 | |
PBDIT/Share (Rs.) | 117.84 | 87.70 | 76.49 | 40.38 | 59.32 | |
PBIT/Share (Rs.) | 101.84 | 81.72 | 69.98 | 33.60 | 51.27 | |
PBT/Share (Rs.) | 62.54 | 87.82 | 53.64 | 33.22 | 50.84 | |
Net Profit/Share (Rs.) | 46.30 | 64.60 | 39.72 | 24.64 | 37.32 | |
Profitability Ratios | ||||||
PBDIT Margin (%) | 17.16 | 16.92 | 19.06 | 12.52 | 18.22 | |
PBIT Margin (%) | 14.83 | 15.77 | 17.44 | 10.42 | 15.75 | |
PBT Margin (%) | 9.11 | 16.94 | 13.37 | 10.30 | 15.62 | |
Net Profit Margin (%) | 6.74 | 12.46 | 9.89 | 7.64 | 11.46 | |
Return on Networth / Equity (%) | 15.02 | 22.68 | 16.86 | 12.04 | 20.45 | |
Return on Capital Employed (%) | 31.23 | 28.34 | 29.11 | 16.03 | 27.20 | |
Return on Assets (%) | 7.62 | 14.98 | 10.08 | 7.19 | 12.04 | |
Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover Ratio (%) | 1.32 | 1.26 | 1.09 | 0.99 | 105.01 | |
Liquidity Ratios | ||||||
Current Ratio (X) | 1.91 | 2.61 | 2.18 | 2.12 | 2.04 | |
Quick Ratio (X) | 1.13 | 1.97 | 1.68 | 1.70 | 1.51 | |
Inventory Turnover Ratio (X) | 4.42 | 0.62 | 0.51 | 0.60 | 5.09 | |
Dividend Payout Ratio (NP) (%) | 51.84 | 24.76 | 20.14 | 8.11 | 5.35 | |
Dividend Payout Ratio (CP) (%) | 38.52 | 22.66 | 17.30 | 6.36 | 4.40 | |
Earnings Retention Ratio (%) | 48.16 | 75.24 | 79.86 | 91.89 | 94.65 | |
Cash Earnings Retention Ratio (%) | 61.48 | 77.34 | 82.70 | 93.64 | 95.60 | |
Valuation Ratios | ||||||
Enterprise Value (Cr.) | 20,979.18 | 12,795.16 | 7,617.77 | 5,940.17 | 7,173.15 | |
EV/Net Operating Revenue (X) | 12.22 | 9.88 | 7.60 | 7.37 | 8.82 | |
EV/EBITDA (X) | 71.21 | 58.36 | 39.84 | 58.85 | 48.37 | |
MarketCap/Net Operating Revenue (X) | 12.54 | 10.27 | 8.09 | 7.93 | 9.25 | |
Retention Ratios (%) | 48.15 | 75.23 | 79.85 | 91.88 | 94.64 | |
Price/BV (X) | 27.93 | 18.68 | 13.79 | 12.49 | 16.50 | |
Price/Net Operating Revenue | 12.54 | 10.27 | 8.09 | 7.93 | 9.25 | |
Earnings Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
31.07.2025
06.06.2025
AstraZeneca Standalone March 2025 Net Sales at Rs 480.48 crore, up 25.39% Y-o-Y
07.04.2025
10.03.2025
06.06.2025
AstraZeneca Standalone March 2025 Net Sales at Rs 480.48 crore, up 25.39% Y-o-Y
17.02.2025
AstraZeneca Standalone December 2024 Net Sales at Rs 440.29 crore, up 43.98% Y-o-Y
21.11.2024
AstraZeneca Standalone September 2024 Net Sales at Rs 408.00 crore, up 31.16% Y-o-Y
13.08.2024
AstraZeneca Standalone June 2024 Net Sales at Rs 387.52 crore, up 31.16% Y-o-Y